Mayne Pharma Group マネジメント

マネジメント基準チェック /14

Mayne Pharma Groupの CEO はShawn O’Brienで、 Oct2022年に任命され、の在任期間は 2.08年です。の年間総報酬はA$ 2.06Mで、 46.5%給与と53.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.075%を直接所有しており、その価値は€ 158.09K 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と2.7年です。

主要情報

Shawn O’Brien

最高経営責任者

AU$2.1m

報酬総額

CEO給与比率	46.5%
CEO在任期間	2.1yrs
CEOの所有権	0.07%
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	2.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Mayne Pharma Group の収益と比較して、Shawn O’Brien の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	AU$2m	AU$959k	-AU$169m
Mar 31 2024	n/a	n/a	-AU$221m
Dec 31 2023	n/a	n/a	-AU$274m
Sep 30 2023	n/a	n/a	-AU$296m
Jun 30 2023	AU$2m	AU$663k	-AU$317m

報酬と市場: Shawnの総報酬 ($USD 1.34M ) は、 German市場 ($USD 846.96K ) の同規模の企業の平均を上回っています。

報酬と収益: Shawnの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Shawn O’Brien (65 yo)

2.1yrs

在職期間

AU$2,062,194

報酬

Mr. Shawn Patrick O'Brien, B.Sc has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'Brien is a found...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% € 158.1k
Aaron Gray	Chief Financial Officer	2.3yrs	AU$1.31m	0.064% € 134.2k
Kimberly Parker	Executive VP & General Counsel	2.8yrs	データなし	データなし
Brant Schofield	Executive Vice President of Corporate Development	3.8yrs	AU$1.29m	データなし
Erinn Nathaniel	Director of Global Human Resources	1.8yrs	データなし	データなし
Daniel Moore	Executive Vice President of Commercial	5.2yrs	データなし	データなし
Frank Casty	Executive VP & Global Chief Medical Officer	1.8yrs	データなし	データなし
Brenton Walter	Financial Controller	20.3yrs	データなし	データなし
Laura Loftus	Associate General Counsel & Company Secretary	4.7yrs	データなし	データなし

2.8yrs

平均在職期間

経験豊富な経営陣: HG6の経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% € 158.1k
Frank Condella	Independent Non-Executive Chairman	6.5yrs	AU$305.40k	0.081% € 171.3k
Bruce Robinson	Independent Non-Executive Director	10.3yrs	AU$219.39k	0.039% € 82.5k
Patrick Blake	Independent Non-Executive Director	6.4yrs	AU$218.36k	0.027% € 57.4k
Ann Custin	Independent Non-Executive Director	2.7yrs	AU$235.16k	0.026% € 55.5k
Kathryn MacFarlane	Independent Non-Executive Director	2.8yrs	AU$215.84k	0.047% € 98.7k
Anne Lockwood	Independent Non Executive Director	less than a year	AU$117.49k	データなし
David Petrie	Non-Executive Director	2.2yrs	AU$217.86k	データなし

2.7yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: HG6の取締役会は経験豊富ではない ( 2.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Mayne Pharma Group マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

High number of new directors

Recent updates

Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023)

No longer forecast to breakeven

New minor risk - Profitability

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

New minor risk - Share price stability

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Now 48% undervalued after recent price drop

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021)

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Mayne Pharma Expands U.S Dermatology Portfolio

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Forecast to breakeven in 2023

Independent Non-Executive Director recently bought €85k worth of stock

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020)

Revenue beats expectations

Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021

Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States

New 90-day high: €0.24

Mayne Pharma Group Limited Provides Update on Women's Health Pipeline

Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer

Full year earnings released

Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020

Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14